A late-breaking presentation at the American Society of Hematology (ASH) 2025 meeting revealed promising phase 3 findings for ...

Ianalumab, a monoclonal antibody, helped patients with immune thrombocytopenia (ITP) maintain safe platelet counts without ...

More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal ...

Novartis is divulging details from ianalumab’s summertime | Novartis is divulging details from ianalumab’s phase 3 win in a rare autoimmune blood disorder, and the data suggest the treatment could del ...

The novel agent, along with standard second-line therapy, may allow patients to stay off treatment for longer periods and may have disease modifying effects when used early in the course of disease.

More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal antibody ianalumab for primary immune thrombocytopenia (ITP), an autoimmune ...

An experimental monoclonal antibody called ianalumab had promising results for more than half of patients with primary immune thrombocytopenia enrolled in a phase 3 trial, according to data published ...

More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal antibody ...

The addition of ianalumab to eltrombopag significantly improved outcomes for patients with pretreated primary immune ...

Microsoft and our third-party vendors use cookies to store and access information such as unique IDs to deliver, maintain and improve our services and ads. If you agree, MSN and Microsoft Bing will ...

Jeff Schaffnit discusses Sanofi's advancements in BTK inhibitors and promising results for hemophilia A therapies at ASH 2025 ...